

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE INTERIM PERIOD 1 JANUARY - 31 MARCH 2020
(ORIGINALLY ISSUED IN TURKISH)**

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE INTERIM PERIOD 1 JANUARY - 31 MARCH 2020**

CONTENTS	PAGE(S)
CONDENSED CONSOLIDATED BALANCE SHEET	1-2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME	3
CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME.....	4
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY	5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW	6-7
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.....	8-38
NOTE 1 ORGANIZATION AND OPERATIONS OF THE GROUP	8-9
NOTE 2 BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	9-11
NOTE 3 SEGMENTAL INFORMATION	12
NOTE 4 CASH AND CASH EQUIVALENTS	13
NOTE 5 FINANCIAL INVESTMENTS.....	13
NOTE 6 FINANCIAL LIABILITIES.....	14-15
NOTE 7 TRADE RECEIVABLES AND PAYABLES.....	16
NOTE 8 OTHER RECEIVABLES AND PAYABLES.....	16-17
NOTE 9 DERIVATIVE INSTRUMENTS.....	17
NOTE 10 INVENTORIES	18
NOTE 11 INVESTMENT PROPERTIES.....	18
NOTE 12 TANGIBLE ASSETS	19-21
NOTE 13 GOODWILL	21
NOTE 14 INTANGIBLE ASSETS	22-23
NOTE 15 OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES.....	23-24
NOTE 16 REVENUE AND COST OF SALES	24
NOTE 17 EXPENSES BY NATURE	25
NOTE 18 INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES	25
NOTE 19 FINANCIAL INCOME	26
NOTE 20 FINANCIAL EXPENSES.....	26
NOTE 21 TAX ASSET AND LIABILITIES	26-29
NOTE 22 EARNINGS PER SHARE	29
NOTE 23 BALANCES AND TRANSACTIONS WITH RELATED PARTIES	30-33
NOTE 24 NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS	33-36
NOTE 25 FINANCIAL INSTRUMENTS	36-37
NOTE 26 EVENTS AFTER THE BALANCE SHEET DATE.....	38

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2020 AND
31 DECEMBER 2019
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)**

		Unaudited Current Period 31 March 2020	Audited Previous Period 31 December 2019
ASSETS	Notes		
Current Assets		9.224.526	8.720.108
Cash and Cash Equivalents	4-2.3	1.219.355	2.027.599
Financial Investments	5-2.3	3.820.230	3.057.459
Trade Receivables			
- Due From Related Parties	7-23	2.390.615	2.106.741
- Other Trade Receivables	7	336.284	259.061
Other Receivables			
- Due From Related Parties	8-23	115.696	115.619
- Other Receivables	8	64.481	37.283
Derivatives Instruments	9	438.068	358.919
Inventories	10	671.929	592.698
Prepaid Expenses			
- Due To Related Parties	23	37.856	41.545
- Other Prepaid Expenses		74.313	42.946
Current Income Tax Assets		4.815	4.583
Other Current Assets		50.884	75.655
Non-Current Assets		4.127.780	4.071.644
Financial Investments	5	946.029	946.029
Other Receivables			
- Other Receivables	8	327	460
Investment Properties	11	21.155	21.155
Tangible Assets	12	2.394.753	2.383.177
Intangible Assets			
- Goodwill	13	402.089	388.047
- Other Intangible Assets	14	317.795	292.188
Prepaid Expenses		5.124	7.602
Deferred Tax Asset	21	40.508	32.986
TOTAL ASSETS		13.352.306	12.791.752

The accompanying notes form an integral part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2020 AND
31 DECEMBER 2019
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

		Unaudited Current Period 31 March 2020	Audited Previous Period 31 December 2019
LIABILITIES	Notes		
Current Liabilities		7.422.098	6.800.011
Short Term Financial Liabilities	6	140.003	150.764
Short Term Portion of Long Term Financial Liabilities	6	5.576.647	5.088.239
Trade Payables			
- Due to related parties	7-23	534.128	607.365
- Other trade payables	7	628.886	617.233
Employee Benefit Related Liabilities		55.926	44.822
Other Payables			
- Due to Related Parties	8-23	3.100	113
- Other Payables	8	3.392	4.994
Deferred Revenue		13.062	11.854
Current Income Tax Liabilities	21	102.249	68.967
Short Term Provisions			
- Short Term Provisions for Employee Benefits		85.415	66.366
- Other Short Term Provisions		242.237	103.331
Other Current Liabilities		37.053	35.963
Non-Current Liabilities		1.000.094	1.057.509
Long Term Financial Liabilities	6	711.872	701.318
Long Term Provisions			
- Long Term Provisions for Employee Benefits		176.946	161.010
Deferred Tax Liabilities	21	111.276	195.181
SHAREHOLDERS' EQUITY		4.930.114	4.934.232
Equity Attributable To Equity Holders' of the Parent		4.320.951	4.411.329
Share Capital		342.000	342.000
Inflation Adjustments to Share Capital		108.056	108.056
Effect of Business Combinations Under Common Control		(485.419)	(485.419)
Other Comprehensive Income/Expense not to be Reclassified to Profit and Loss			
- Increases on Revaluation of Plant, Property and Equipment		647.779	647.779
- Actuarial Gains and Losses on Post-Employment Termination Benefit Obligation		(29.871)	(26.435)
- Gains from Financial Assets Measured at Fair Value Through Other Comprehensive Income		513.939	513.939
- Other Gains		817.879	817.879
Other Comprehensive Income/Expense to be Reclassified to Profit and Loss			
- Currency Translation Adjustments		(48.106)	(57.006)
- Cash Flow Hedges		6.145	3.695
Restricted Reserves		131.587	131.587
Retained Earnings		2.415.254	1.509.952
Net (Loss)/Profit for the Period		(98.292)	905.302
Non-Controlling Interest		609.163	522.903
TOTAL LIABILITIES AND EQUITY		13.352.306	12.791.752

The accompanying notes form an integral part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME FOR THE INTERIM PERIOD ENDED
31 MARCH 2020 AND 2019
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

	Notes	Unaudited Current Period 1 January - 31 March 2020	Unaudited Previous Period 1 January - 31 March 2019
PROFIT OR LOSS			
Revenue	16	2.376.126	1.942.360
Cost of Sales	16	(1.659.845)	(1.404.188)
GROSS PROFIT FROM OPERATIONS		716.281	538.172
General Administrative Expenses	17	(63.816)	(38.613)
Marketing, Sales and Distribution Expenses	17	(275.631)	(206.804)
Research and Development Expenses	17	(5.682)	(3.836)
Other Operating Income		54.783	31.776
Other Operating Expenses		(28.728)	(24.314)
OPERATING PROFIT FROM MAIN OPERATIONS		397.207	296.381
Income from Investment Activities	18	725.238	553.322
Expenses from Investment Activities	18	(672.328)	(25.055)
OPERATING PROFIT BEFORE FINANCIAL INCOME AND EXPENSES		450.117	824.648
Financial Income	19	7.697	2.005
Financial Expenses	20	(528.393)	(322.380)
(LOSS)/PROFIT BEFORE TAX		(70.579)	504.273
Tax Income/(Expense)		26.436	(104.827)
Corporate Tax Expense	21	(67.338)	(108.769)
Deferred Tax Income	21	93.774	3.942
(LOSS)/PROFIT FOR THE PERIOD		(44.143)	399.446
Distribution of the (Loss)/Profit for the Period			
Non-Controlling Interest		54.149	33.970
Equity Holders of the Parent		(98.292)	365.476
(Loss)/Earnings per Share	22	(0,29)	1,07

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME FOR THE INTERIM
PERIOD ENDED 31 MARCH 2020 AND 2019**
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

	Unaudited Current Period 1 January - 31 March 2020	Unaudited Previous Period 1 January - 31 March 2019
(LOSS)/PROFIT FOR THE PERIOD	(44.143)	399.446
Other Comprehensive Income		
Not to be Reclassified To Profit and Loss	(3.516)	-
Actuarial Loss on Post-Employment Termination Benefit Obligation	(4.395)	-
Deferred Tax for the Items That Will not be Reclassified in Profit and Loss		
Actuarial Loss on Post-Employment Termination Loss Obligation, Deferred Tax Effect	879	-
Items to be Reclassified to Profit and Loss	43.541	46.172
Currency Translation Adjustments	41.091	35.841
Cash Flow Hedges	3.141	13.245
Deferred Tax For The Items That Will be Reclassified to Profit and Loss		
Cash Flow Hedges, Deferred Tax Effect	(691)	(2.914)
OTHER COMPREHENSIVE INCOME	40.025	46.172
TOTAL COMPREHENSIVE (EXPENSE)/INCOME	(4.118)	445.618
Distribution of Total Comprehensive (Expense)/Income		
Non-Controlling Interest	86.260	50.917
Equity Holders of the Parent	(90.378)	394.701

The accompanying notes form an integral part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE PERIOD ENDED 31 MARCH 2020 AND 2019

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

	Accumulated Other Comprehensive Income To Be Reclassified Under Profit And Loss		Accumulated Other Comprehensive Income Not To Be Reclassified To Profit And Loss					Accumulated Profit							
	Share Capital	Inflation Adjustments to Share Capital	Effect of Business Combinations Under Common Control	Currency Translation Adjustments	Cash Flow Hedges	Revaluation Plant, Property and Equipment	Actuarial Losses on Post-Employment Termination Benefit Obligation	Financial Assets Fair Value Through Other Comprehensive Income	Other Gains	Restricted Reserves Appropriated from Profits	Net Profit/(Loss) for the Period	Retained Earnings	Equity Attributable to Equity Holders of the Parent	Non-Controlling Interest	Total
As of 1 January 2019	342.000	108.056	(498.670)	(89.429)	52.481	647.779	(21.173)	1.099.942	-	131.587	700.779	822.885	3.296.237	383.495	3.679.732
Transfer	-	-	-	-	-	-	-	-	-	-	(700.779)	700.779	-	-	-
Total comprehensive income	-	-	-	18.894	10.331	-	-	-	-	-	365.476	-	394.701	50.917	445.618
As of 31 March 2019	342.000	108.056	(498.670)	(70.535)	62.812	647.779	(21.173)	1.099.942	-	131.587	365.476	1.523.664	3.690.938	434.412	4.125.350
As of 1 January 2020	342.000	108.056	(485.419)	(57.006)	3.695	647.779	(26.435)	513.939	817.879	131.587	905.302	1.509.952	4.411.329	522.903	4.934.232
Transfer	-	-	-	-	-	-	-	-	-	-	(905.302)	905.302	-	-	-
Total comprehensive income	-	-	-	8.900	2.450	-	(3.436)	-	-	-	(98.292)	-	(90.378)	86.260	(4.118)
As of 31 March 2020	342.000	108.056	(485.419)	(48.106)	6.145	647.779	(29.871)	513.939	817.879	131.587	(98.292)	2.415.254	4.320.951	609.163	4.930.114

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL
STATEMENTS ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED
31 MARCH 2020 AND 2019
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)**

		Unaudited Current Period 1 January - 31 March 2020	Unaudited Previous Period 1 January - 31 March 2019
	Notes		
CASH FLOWS FROM OPERATING ACTIVITIES			
Net (Loss)/Profit for the Period		(44.143)	399.446
Adjustments to Reconcile Net (Loss)/Profit			
Adjustment for Depreciation and Amortization Expenses			
Depreciation expenses of tangible assets	12	43.455	40.052
Amortization expenses of intangible assets	14	560	1.237
Adjustment for Impairment Loss (Reversal)			
Provision for/(reversal of) doubtful receivables	7	827	(1.356)
Adjustment for impairment loss (reversal) of other financial investments			
Increase in financial investments	18	-	(166.764)
Decrease in financial investments	18	568.686	-
Adjustment for impairment loss of inventories	10	4.841	5.279
Adjustment for Provisions			
Adjustments for Provisions (Cancelled) Related with Employee Benefits			
Provision for employment benefits		13.491	15.555
Provision for unused vacation		6.412	2.956
Provision for premium		9.509	4.908
Adjustments for Provision (Cancelled) Lawsuits		47	304
Adjustments for Other Provisions			
Change in Other Provisions (net)		139.074	105.017
Adjustments for Interest Income and Expense			
Adjustments for Interest Income			
Interest income	18	(31.291)	(52.757)
Adjustments for Interest Expense			
Interest expense	20	93.500	84.113
Rediscounted interest expense (net)		-	418
Adjustment for Tax Expenses	21	(26.436)	104.827
Adjustments for Losses (Gains) on Disposals of Non-Current Assets			
Adjustments for (gains)/losses arised from sale of tangible assets	18	(1.240)	955
Adjustments for Losses (Gains) on Disposals of Other Items			
Whose Cash Effects are Investing or Financing Cash Flow			
Change in foreign currency of financial liabilities (net)	19-20	421.152	220.333
Change in foreign currency from investing activities (net)	18	(586.056)	(307.297)
Commission expenses and finance service income (net)	19-20	6.044	15.929
Other Adjustments to Reconcile Profit/(Loss)			
Rent income	18	(3.009)	(2.404)
Net operating cash flows provided before changes in working capital		615.423	470.751

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL
STATEMENTS ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED
31 MARCH 2020 AND 2019
(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)**

		Unaudited Current Period 1 January - 31 March 2020	Unaudited Previous Period 1 January - 31 March 2019
	Notes		
Changes in Working Capital			
Increase in trade receivables		(27.784)	(68.880)
Increase in trade receivables from related parties		(283.874)	(300.258)
(Increase)/decrease in inventories		(70.117)	18.897
(Increase)/decrease in other receivables and other current assets		(26.175)	3.797
Decrease in trade payables		(10.255)	(55.468)
(Decrease)/increase in trade payables to related parties		(73.237)	3.853
Decrease in other payables and liabilities		(936)	(14.658)
Net cash generated from operations		123.045	58.034
Payments related with provisions for employee benefits			
Employment termination benefit paid		(6.460)	(4.515)
Unused vacation paid		(4.834)	(1.375)
Performance premium paid		(66)	-
Lawsuits provision paid		(47)	(56)
Taxes paid		(34.288)	(780)
Collections from doubtful trade receivables	7	149	348
Net cash generated from operating activities		77.499	51.656
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from sales of tangible and intangible assets		2.515	2.219
Purchase of property, plant and equipment		(23.821)	(21.104)
Purchase of intangible assets		(1.740)	(1.483)
Changes in non-trade receivables from related parties		(77)	(59)
Interest received		31.291	52.757
Repayments from other given advances and payables		2.478	2.563
Rent income		3.009	2.404
Cash outflows from purchase of other businesses or share of funds or debt instruments		(943.351)	(4.557)
Net cash (used in)/generated from investing activities		(929.696)	32.740
CASH FLOWS FROM FINANCING ACTIVITIES			
Cash inflow from borrowings		17.215	-
Repayments of borrowings		(73.016)	(21.104)
Comission paid		6.044	15.929
Interest paid		(37.928)	(33.311)
Change in non-trade payables to related parties		2.987	1.522
Net cash used in financing activities		(96.786)	(68.822)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(948.983)	15.574
THE EFFECT OF FOREIGN EXCHANGE RATE			
CHANGE ON CASH AND CASH EQUIVALENTS		140.739	90.549
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD		2.027.599	999.462
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD		1.219.355	1.105.585

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

1. ORGANIZATION AND OPERATIONS OF THE GROUP

Ülker Bisküvi Sanayi A.Ş. (“the Company”) and its subsidiaries (all together “the Group”), comprises of the parent Ülker Bisküvi Sanayi A.Ş. (“the Company”) and fourteen subsidiaries in which the Company owns the majority share of the capital or which are controlled by the Company (2019: Fourteen)

Ülker Bisküvi Sanayi A.Ş. was established in 1944. The Company’s core business activities are manufacturing of biscuits, chocolate, chocolate coated biscuits, wafers and cakes.

Ülker Bisküvi Sanayi A.Ş. which is registered at the Capital Market Board, merged under its own title with Anadolu Gıda Sanayi A.Ş., whose shares have been quoted on Borsa Istanbul since 30 October 1996, as of 31 December 2003.

The headquarter of Ülker Bisküvi Sanayi A.Ş. is located Kısıklı Mah. Ferah Cad. No:1 Büyük Çamlıca Üsküdar/Istanbul.

As of 31 March 2020, the total number of people employed by the Group is 9.149, which contains 1.525 employees who worked as subcontractors (31 December 2019: 8.921, subcontractor: 1.276).

The ultimate parent and the controlling party of the Group is pladis Foods Limited. The ultimate controlling party is Yıldız Holding A.Ş.. pladis Foods Limited is subsidiary of Yıldız Holding A.Ş. with a shares of 100%. Yıldız Holding A.Ş. is managed by Ülker Family.

As of 31 March 2020 and 31 December 2019, the names and percentages of the shareholders holding more than 5% of the Company’s share capital are as follows:

Name of the Shareholders	Share	31 March 2020	Share	31 December 2019
		Ratio		Ratio
pladis Foods Limited	174.420	51,00%	174.420	51,00%
Ülker Family Members and Yıldız Holding A.Ş.	25.580	7,48%	25.580	7,48%
Other	142.000	41,52%	142.000	41,52%
	342.000	100,00%	342.000	100,00%

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

1. ORGANIZATION AND OPERATIONS OF THE GROUP (Continued)

As of 31 March 2020 and 31 December 2019, the details of the subsidiaries under consolidation in terms of direct and effective share of ownership and principal business activities are as follows:

Subsidiaries	31 March 2020		31 December 2019		Nature of Operation
	Ratio of Direct Ownership	Ratio of Effective Ownership	Ratio of Direct Ownership	Ratio of Effective Ownership	
Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş.	73,9%	73,9%	73,9%	73,9%	Manufacturing
Ülker Çikolata Sanayi A.Ş.	91,7%	91,7%	91,7%	91,7%	Manufacturing
Atlas Gıda Pazarlama Sanayi ve Ticaret A.Ş.	100,0%	100,0%	100,0%	100,0%	Trading
Reform Gıda Paz. San. ve Tic. A.Ş.	100,0%	100,0%	100,0%	100,0%	Trading
UI Egypt B.V.	51,0%	51,0%	51,0%	51,0%	Investing
Hi-Food for Advanced Food Industries	-	51,4%	-	51,4%	Manufacturing/Sales
Sabourne Investments Ltd	100,0%	100,0%	100,0%	100,0%	Investing
Food Manufacturers’ Company	-	55,0%	-	55,0%	Manufacturing/Sales
Hamle Company Ltd LLP	100,0%	100,0%	100,0%	100,0%	Manufacturing/Sales
Ulker Star LLC	-	99,0%	-	99,0%	Sales
UI Mena BV	100,0%	100,0%	100,0%	100,0%	Investing
Amir Global Trading FZE	-	100,0%	-	100,0%	Sales
Ulker for Trading and Marketing	-	99,8%	-	99,8%	Sales
International Biscuits Company	100,0%	100,0%	100,0%	100,0%	Manufacturing/Sales

Approval of Financial Statements:

The Board of Directors has approved the financial statements and given authorization for the issuance on 4 May 2020. The General Assembly has the authority to amend/modify the financial statements.

2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS

2.1 Basis of the Presentation

Principles for Preparation of Financial Statements and Significant Accounting Policies

The accompanying consolidated financial statements are prepared in accordance with Communiqué Serial II, No:14.1, “Principles of Financial Reporting in Capital Markets” (“the Communiqué”) published in the Official Gazette numbered 28676 on 13 June 2013. According to Article 5 of the Communiqué, consolidated financial statements are prepared in accordance with the Turkish Accounting Standards (“TAS”) issued by Public Oversight Accounting and Auditing Standards Authority (“POAASA”). TAS contains Turkish Accounting Standards, Turkish Financial Reporting Standards (“TFRS”) and its addendum and interpretations.

The consolidated financial statements of the Group are prepared as per the CMB announcement of 7 June 2013 relating to financial statements presentations.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

2.1 Basis of the Presentation (Continued)

Principles for Preparation of Financial Statements and Significant Accounting Policies (Continued)

In accordance with the CMB resolution issued on 17 March 2005, listed companies operating in Turkey are not subject to inflation accounting effective from 1 January 2005. Therefore, the consolidated financial statements of the Group have been prepared accordingly.

The Company and Subsidiaries in Turkey maintain their books of accounts and prepare their statutory financial statements in accordance with the Turkish Commercial Code ("TCC"), tax legislation, the Uniform Chart of Accounts issued by the Ministry of Finance and principles issued by CMB. The foreign subsidiaries maintain their books of account in accordance with the laws and regulations in force in the countries in which they are registered. These consolidated financial statements have been prepared under historical cost conventions except for land, buildings, financial assets and financial liabilities which are carried at fair value. The consolidated financial statements are based on the statutory records, which are maintained under historical cost conventions.

Functional and Presentation Currency

Financial statements of each subsidiary of the Group are presented in the currency of the primary economic environment in which the entities operate (its functional currency). The results and financial position of the each subsidiary are expressed in Turkish Lira, which is the presentation currency of the Group.

As of 31 March 2020, rates declared by Central Bank of Republic of Turkey are;
1 Euro = 7,2150 TL, 1 USD 6,5160 TL, 1 EGP = 0,4141 TL, 1 SAR = 1,7345 TL, 1 KZT = 0,0145 TL,
1 AED = 1,7755 TL (31 December 2019: 1 Euro = 6,6506 TL, 1 USD 5,9402 TL, 1 EGP = 0,3703 TL,
1 SAR = 1,5834 TL, 1 KZT = 0,0156 TL, 1 AED = 1,6186 TL). For the period between 1 January 2020 and
31 March 2020, average rates declared by Central Bank of Republic of Turkey are; 1 Euro = 6,7204 TL,
1 USD = 6,0921 TL, 1 EGP = 0,3868 TL, 1 SAR = 1,6235 TL, 1 KZT = 0,0156 TL, 1 AED = 1,6601 TL
(1 January – 31 March 2019: 1 Euro = 6,0928 TL, 1 USD = 5,3629 TL, 1 EGP = 0,3047 TL,
1 SAR = 1,4299 TL, 1 KZT = 0,0142 TL, 1 AED = 1,4614 TL)

2.2 New and Revised International Financial Reporting Standards

The Group has applied the standards which are relevant to its operations from the standards, amendments and interpretation applicable from 1 January 2020.

Standards, amendments and interpretations applicable as at 31 March 2020:

Amendments to TAS 1 and TAS 8 on the definition of material; effective from Annual periods beginning on or after 1 January 2020.

Amendments to TFRS 3 - definition of a business; effective from Annual periods beginning on or after 1 January 2020.

Amendments to TFRS 9, IAS 39 and TFRS 7 – Interest rate benchmark reform; effective from Annual periods beginning on or after 1 January 2020.

Standards, amendments and interpretations that are issued but not effective as at 31 March 2020:

TFRS 17, 'Insurance contracts'; effective from annual periods beginning on or after 1 January 2022.

Amendments to IAS 1 - Presentation of financial statements' on classification of liabilities; effective from 1 January 2022.

The Group is in the process of assessing the impact of the amendments on financial position or performance of the Group.

The Group has finalized their assessments for TFRS 16 "Leases" as of 31 March 2020, and concluded that IFRS 16 does not have a significant impact on the consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

2.3 Comparative Information and Restatement/Reclassification of Prior Period Consolidated Financial Statements

Accounting policy changes are applied retrospectively and the previous year financial statements are rearranged and reclassified.

In order to allow the determination of financial position and performance, the Group's consolidated financial statements are prepared in comparison with the previous period. In order to comply with the presentation of consolidated financial statements the current period when deemed necessary, comparative information is reclassified, and material differences are presented. The Group has made some reclassifications to prior period financials in order to conform to current period financial statements.

The Group management previously accounted its liquid funds under cash and cash equivalents with the expectation of insignificant risk of changes in value. However; due to the fluctuations in global financial markets in the current year, the Group management decided to reclassify liquid funds to short-term financial investments. In order to provide comparative information, previous period amounts are also reclassified into short-term financial investments.

Effects of the related changes on the consolidated financial statements as of 31 December 2019 and interim condensed consolidated financial statements ending as of 31 March 2019 as follows.

	31 December 2019	Effects of	31 December 2019
	Reclassified	Reclassification	Reported
Condensed consolidated financial statements			
Cash and cash equivalents	2.027.599	(3.053.379)	5.080.978
Short term financial investments	3.057.459	3.053.379	4.080
	1 January- 31 March 2019	Effects of	1 January- 31 March 2019
	Reclassified	Reclassification	Reclassified
Condensed consolidated cash flow			
Net cash generated from investing activities	32.740	(171.321)	204.061
Cash and cash equivalents at the end of the period	1.105.585	(2.724.421)	3.830.006

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

3. SEGMENTAL INFORMATION

The Group's core business activities are manufacturing and marketing of biscuit, chocolate coated biscuit, wafer, cake and chocolate. The reports reviewed routinely by the decision makers of the Group comprise consolidated financial information of Ülker Bisküvi Sanayi A.Ş. and its subsidiaries. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the board of directors that makes strategic decisions. The Group management has determined the operating segments based on the reports reviewed by the board of directors that are used to make strategic decisions. The board of directors review segmental analysis on gross profit and operational profit.

The Group, follows its operations with domestic (local operations of Turkish companies in Turkey) and international basis in accordance with TFRS 8. The information for 1 January - 31 March 2020 and 1 January - 31 March 2019.

	Domestic	Foreign	1 January - 31 March 2020
Revenue	1,474.956	901.170	2,376.126
Gross Profit	354.663	361.618	716.281
Operating Profit (*)	199.906	171.246	371.152
EBITDA (**)	221.672	193.495	415.167
EBITDA/Revenue	15,0%	21,5%	17,5%
Investment Expense	12.705	10.963	23.669
	Domestic	Foreign	1 January - 31 March 2019
Revenue	1,202.223	740.137	1,942.360
Gross Profit	265.601	272.571	538.172
Operating Profit (*)	154.417	134.502	288.919
EBITDA (**)	174.773	155.435	330.208
EBITDA/Revenue	14,5%	21,0%	17,0%
Investment Expense	9.323	13.264	22.587

(*) Profit before other income/expense.

(**) EBITDA (Earnings before interest, tax, depreciation and amortization) is calculated by adding back the non-cash expenses of depreciation and amortization to a firm's operating income. EBITDA isn't a measure of performance identified in TFRS, thus it may not be a tool for comparison for firms.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

4. CASH AND CASH EQUIVALENTS

	31 March 2020	31 December 2019
Cash on hand	1.883	180
Demand deposits	486.391	344.705
Time deposits	737.853	1.689.735
Impairment provision	(6.772)	(7.021)
	1.219.355	2.027.599

Details of time deposits are shown below:

Currency Type	Annual Weighted Average Effective Interest Rate	Maturity	31 March 2020
TL	9,94%	April 2020	248.368
EUR	0,01%	April 2020	11.902
USD	0,98%	April 2020	400.287
GBP	0,05%	April 2020	11.368
EGP	9,18%	April 2020	49.731
KZT	10,00%	April 2020	16.197
			737.853

Currency Type	Annual Weighted Average Effective Interest Rate	Maturity	31 December 2019
TL	11,08%	January 2020	221.828
EUR	0,05%	January 2020	20.879
USD	2,69%	January 2020	1.396.246
GBP	0,15%	January 2020	5.217
EGP	11,01%	January 2020	21.925
KZT	10,00%	January 2020	23.640
			1.689.735

5. FINANCIAL INVESTMENTS

Short Term Financial Investments:	31 March 2020	31 December 2019
Available for sale financial assets (*)	3.820.230	3.057.459
	3.820.230	3.057.459

Long Term Financial Investments:	31 March 2020	31 December 2019
Available for sales financial assets (**)	946.029	946.029
	946.029	946.029

Long Term Available for Sale Financial	31 March 2020	31 December 2019
G New, Inc	312.171	312.171
Godiva Belgium BVBA	633.658	633.658
Other	200	200
	946.029	946.029

(*) TL 3.815.172 thousands of short term financial investments consists of liquid mutual funds with a maturity of less than 3 months.

(**) Available for sale long term financial assets are presented at their fair values. Net changes in fair value of available for sale financial assets attributable to shareholders as at 31 March 2020 amounting to TL 513.939 thousand have been directly presented in other comprehensive income under equity

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

6. FINANCIAL LIABILITIES

	31 March 2020	31 December 2019
Short term liabilities	140.003	150.764
Short term portion of long term liabilities	5.576.647	5.088.239
Long term liabilities	711.872	701.318
	6.428.522	5.940.321
<u>Short Term Liabilities</u>	<u>31 March 2020</u>	<u>31 December 2019</u>
Bank loans	12.355	66.437
Non-trade payables to related parties (Note 23)	127.648	84.327
	140.003	150.764
<u>Short Term Portion of Long Term Liabilities</u>	<u>31 March 2020</u>	<u>31 December 2019</u>
Bank loans	5.560.634	5.074.414
Financial lease payables	16.013	13.825
	5.576.647	5.088.239
<u>Long Term Liabilities</u>	<u>31 March 2020</u>	<u>31 December 2019</u>
Bank loans	667.124	652.490
Financial lease payables	44.748	48.828
	711.872	701.318

The group has used a syndication loan in 20 April 2017. Details of Group's syndication loans are as follows: Syndication loan consists of two credit trenches which are USD 136.000.000 and EUR 225.144.922. 14 international banks joined to the syndication. Effective interest rate for both credit trenches are Euribor + 3,00 % for EUR, Libor + 3,10 % for USD and the maturity date is 20 April 2020. Principal payments of the loans are repaid at maturity with semi-annual interest payments.

In addition to syndication loan used in April 2017, the group has used a new syndication loan consists of two credit trenches which are USD 111.498.684 and EUR 290.559.069. 15 international banks joined to the syndication. Effective interest rate for both credit trenches are Euribor + 3.00% for EUR , Libor + 2.90% for USD and the maturity date is 27 November 2020. Principal payments of the loans are repaid at maturity with semi-annual interest payments

The covenants which belong to syndicated loan are as follows:

a) Leverage: The ratio of the consolidated net debt at balance sheet date to the last twelve months consolidated EBITDA (Earnings before interest, tax, depreciation and amortization) in the valid period should not be over 3,50 to 1.

b) Interest Coverage: Consolidated interest coverage ratio of the Group should be at least 2 to 1.

In current year, the consolidated financial statements of the Group comply with the covenants of the syndication loan agreement.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

6. FINANCIAL LIABILITIES (Continued)

Liabilities:

31 March 2020

<u>Currency Type</u>	<u>Maturity</u>	<u>Effective Weighted Average Interest Rate (%)</u>	<u>Short Term</u>	<u>Long Term</u>
TL	April 2020-April 2023	16,36%	143.661	44.748
EUR	May 2020-May 2023	3,01%	3.913.954	413.352
USD	April 2020-November 2020	4,93%	1.646.680	-
KZT	April 2020-January 2026	10,00%	7.095	253.772
SAR	July 2020	4,76%	5.260	-
			<u>5.716.650</u>	<u>711.872</u>

31 December 2019

<u>Currency Type</u>	<u>Maturity</u>	<u>Effective Weighted Average Interest Rate (%)</u>	<u>Short Term</u>	<u>Long Term</u>
TL	January 2020-April 2023	18,72%	98.153	48.828
EUR	February 2020-May 2023	3,01%	3.585.375	379.467
USD	January 2020-November 2020	4,92%	1.539.388	-
KZT	January 2020-January 2026	10,00%	6.379	273.023
SAR	January 2020-July 2020	4,00%	9.708	-
			<u>5.239.003</u>	<u>701.318</u>

The maturity detail of the bank loans is as follows:

	<u>31 March 2020</u>	<u>31 December 2019</u>
to be paid within 1 year	5.700.637	5.225.178
to be paid within 1-2 years	244.690	273.085
to be paid within 2-3 years	226.507	215.508
to be paid within 3-4 years	99.252	98.892
to be paid within 4-5 years	48.337	52.004
Above 5 years	48.338	13.001
	<u>6.367.761</u>	<u>5.877.668</u>

Short Term Financial Lease Liabilities

	<u>31 March 2020</u>	<u>31 December 2019</u>
Financial lease liabilities	30.505	29.282
Future finance charges on finance leases (-)	(14.492)	(15.457)
	<u>16.013</u>	<u>13.825</u>

Long Term Financial Lease Liabilities

	<u>31 March 2020</u>	<u>31 December 2019</u>
Financial lease liabilities	58.574	65.895
Future finance charges on finance leases (-)	(13.826)	(17.067)
	<u>44.748</u>	<u>48.828</u>

The maturity detail of the financial lease liabilities is as follows:

	<u>31 March 2020</u>	<u>31 December 2019</u>
to be paid within 1 year	16.013	13.825
to be paid within 1-2 years	19.373	18.108
to be paid within 2-3 years	25.375	23.720
to be paid within 3-4 years	-	7.000
	<u>60.761</u>	<u>62.653</u>

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

7. TRADE RECEIVABLES AND PAYABLES

	31 March 2020	31 December 2019
Short Term Due from Related Parties		
Due from related parties (Note 23)	2.390.615	2.106.741
	2.390.615	2.106.741
Other Trade Receivables		
Trade receivables	347.556	269.750
Notes receivables	657	84
Provision for doubtful receivables	(11.929)	(10.773)
	336.284	259.061
Total Short Term Trade Receivables	2.726.899	2.365.802

The movement of the allowance for doubtful receivables as of 31 March 2020 and 2019 is as follows:

	31 March 2020	31 March 2019
Opening balance	(10.773)	(19.351)
Current period expense	(881)	(855)
Canceled provision	54	2.211
Currency translation differences	(478)	(905)
Collection	149	348
Closing balance	(11.929)	(18.552)

	31 March 2020	31 December 2019
Short Term Trade Payables		
Due to related parties (Note 23)	534.128	607.365
Trade payables	628.886	617.233
	1.163.014	1.224.598

8. OTHER RECEIVABLES AND PAYABLES

	31 March 2020	31 December 2019
Other Receivables		
Due from related parties (Note 23)	115.696	115.619
Short term other receivables	64.481	37.283
	180.177	152.902
Other Short Term Receivables		
VAT receivables	41.070	17.229
Deposits and guarantees given	20.585	18.277
Receivables from personnel	1.532	1.568
Other	1.294	209
	64.481	37.283

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

8. OTHER RECEIVABLES AND PAYABLES (Continued)

	31 March 2020	31 December 2019
Other Long Term Receivables		
Deposits and guarantees given	327	460
	327	460
	31 March 2020	31 December 2019
Other Payables		
Due from related parties (Note 23)	3.100	113
Other short term payables	3.392	4.994
	6.492	5.107
	31 March 2020	31 December 2019
Other Short Term Payables		
Deposits and guarantees received	124	124
Other short term payables	3.268	4.870
	3.392	4.994

9. DERIVATIVE INSTRUMENTS

As date of 20 April 2017, the Group received syndication loans which are USD 136.000.000 and EUR 225.144.922 respectively. Principal payments of the loans are repaid at maturity with semi-annual interest payments in parallel with repayment schedule, the Group entered into a cross currency fixed interest rate swap contracts amounting to USD 116.000.000 and EUR 30.000.000, respectively to manage its exposure to interest rate and foreign currency fluctuations.

Derivative instruments as of 31 March 2020 and 31 December 2019 are as follows:

	31 March 2020		31 December 2019	
	Contract Amount	Fair Value	Contract Amount	Fair Value
Derivative instruments held for hedge				
Cross Currency Fixed Interest Rate Swap	528.132	438.068	528.132	358.919
Total Asset	528.132	438.068	528.132	358.919

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

10. INVENTORIES

Details of inventory are as follows;

	31 March 2020	31 December 2019
Raw materials	295.058	231.633
Work in progress	24.497	24.430
Finished goods	287.603	272.475
Trade goods	32.846	34.347
Other inventories	54.169	47.843
Allowance for impairment on inventory(-)	(22.244)	(18.030)
	671.929	592.698

Inventory is presented on cost value and allowance for impairment is booked for inventory valuing lower than cost.

The movement of allowance for impairment on inventory for the periods ended on 31 March 2020 and 2019 are below:

	1 January- 31 March 2020	1 January- 31 March 2019
Opening balance	(18.030)	(11.829)
Charge for the period	(4.841)	(5.279)
Reversal of provision	1.191	784
Currency translation differences	(564)	(380)
Closing balance	(22.244)	(16.704)

11. INVESTMENT PROPERTIES

	1 January- 31 March 2020	1 January- 31 March 2019
Opening balance	21.155	21.036
Closing balance	21.155	21.036

The fair value of the Group's investment properties at 31 March 2020 has been calculated on the basis of a valuation carried out at that date by 31 December 2019, by independent valuers not related to the Group. NOVA Taşınmaz Değerleme ve Danışmanlık A.Ş. is one of the accredited independent valuers by Capital Markets Board of Turkey, and has appropriate qualifications and recent experience in the valuation of properties in the relevant locations. The valuation, which conforms to International Valuation Standards, based on market evidence of transaction prices for similar properties.

The rent income earned by the Group from its investment properties amounting to TL 360 thousand (31 March 2019: TL 296 thousand) as of 31.March 2020. Direct operating expenses arising from the investment properties in the current period amounting to TL 13 thousand. (31 March 2019: TL 12 thousand).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

12. TANGIBLE ASSETS

Movement of tangible assets between 1 January 2020 and 31 March 2020 is as follows:

Cost	1 January 2020	Addition	Disposal	Transfer	Currency Translation Differences	31 March 2020
Land	720.030	-	-	-	2.182	722.212
Buildings	820.437	5.773	-	701	13.771	840.682
Machinery, plant and equipment	2.197.143	7.029	(2.662)	23.470	51.079	2.276.059
Vehicles	12.656	-	(25)	-	427	13.058
Furniture and fixture	112.036	1.337	(430)	3.035	3.998	119.976
Leasehold improvements	41.518	70	(11)	-	27	41.604
Other tangible assets	975	-	-	-	93	1.068
Construction in progress	63.648	7.720	(824)	(27.206)	874	44.212
	3.968.443	21.929	(3.952)	-	72.451	4.058.871
Accumulated Depreciation	1 January 2020	Charge for the Period	Disposal	Transfer	Currency Translation Differences	31 March 2020
Buildings	(377.766)	(5.728)	-	-	(4.696)	(388.190)
Machinery, plant and equipment	(1.095.425)	(34.180)	2.224	-	(30.269)	(1.157.650)
Vehicles	(9.143)	(360)	25	-	(423)	(9.901)
Furniture and fixture	(78.955)	(2.182)	425	-	(3.074)	(83.786)
Leasehold improvements	(22.893)	(973)	3	-	(11)	(23.874)
Other tangible assets	(1.084)	(32)	-	-	399	(717)
	(1.585.266)	(43.455)	2.677	-	(38.074)	(1.664.118)
Net Book Value	2.383.177					2.394.753

From depreciation and amortization expenses, TL 41.546 thousand (31 March 2019: TL 37.781 thousand) is included in cost of goods sold, TL 91 thousand (31 March 2019: TL 107 thousand) is included in research and development expenses, TL 980 thousand (31 March 2019: TL 777 thousand) is included in marketing and selling expenses, TL 1.398 thousand (31 March 2019: TL 2.624 thousand) is included in general and administrative expenses. There is not any mortgage or collateral on tangible assets in the current period. There are not any fixed assets acquired through financial leasing as of 31 March 2020.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

12. TANGIBLE ASSETS (Continued)

Movement of tangible assets between 1 January 2019 and 31 March 2019 is as follows:

Cost	1 January 2019	Addition	Disposal	Transfer	Currency Translation Differences	31 March 2019
Land	714.750	-	-	32	2.243	717.025
Buildings	698.303	504	-	697	14.196	713.700
Machinery, plant and equipment	2.038.567	3.582	(2.542)	3.725	50.714	2.094.046
Vehicles	11.697	-	(249)	-	507	11.955
Furniture and fixture	95.810	1.290	(40)	3	2.233	99.296
Leasehold improvements	41.326	348	-	-	17	41.691
Other tangible assets	798	-	-	-	56	854
Construction in progress	44.470	15.380	(547)	(4.457)	2.655	57.501
	3.645.721	21.104	(3.378)	-	72.621	3.736.068
Accumulated Depreciation	1 January 2019	Charge for the Period	Disposal	Transfer	Currency Translation Differences	31 March 2019
Buildings	(346.062)	(4.984)	-	-	(5.602)	(356.648)
Machinery, plant and equipment	(925.608)	(31.723)	98	-	(21.824)	(979.057)
Vehicles	(7.054)	(409)	67	-	(371)	(7.767)
Furniture and fixture	(70.149)	(1.915)	39	-	(1.557)	(73.582)
Leasehold improvements	(19.545)	(1.001)	-	-	(5)	(20.551)
Other tangible assets	(937)	(20)	-	-	(34)	(991)
	(1.369.355)	(40.052)	204	-	(29.393)	(1.438.596)
Net Book Value	2.276.366					2.297.472

There is not any fixed asset acquired through financial leasing as of 31 March 2019. There is not any mortgage or collateral on tangible assets in the current period.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

12. TANGIBLE ASSETS (Continued)

The estimated useful lives of tangible assets are as follow:

	Useful Life
Buildings	25 – 50 year
Machinery, plant and equipments	4 – 20 year
Vehicles	4 – 10 year
Other tangible assets	4 – 10 year
Furniture and fixtures	3 – 10 year
Leasehold improvements	During rent period

The Group decided to apply revaluation model to land and buildings in accordance with TMS 16. Land and buildings were revalued with “compare with similars” technique on 15 January 2018. The revaluation was performed by Nova Taşınmaz Değerleme ve Danışmanlık A.Ş. authorized by Capital Markets Board. Properties were accounted on 31 December 2017 financial statements based on their fair values. The frequency of revaluations are related with the changes on the market values of the properties. If there is material change at the fair value, revaluation is performed. If not, properties are only subject to periodical revaluation.

13. GOODWILL

	31 March 2020	31 December 2019
1 January	388.047	331.975
Currency translation difference	14.042	56.072
Closing Balance	402.089	388.047

Goodwill details are as follow:

Company	31 March 2020	31 December 2019
UI Mena B.V.	386.779	373.272
IBC	15.310	14.775
	402.089	388.047

UI Mena B.V.

Yıldız Holding A.Ş. acquired United Biscuit Group as of 3 November 2014. Goodwill accounted at Yıldız Holding’s financial statement related with UI MENA operations is accounted to these financial statement by restating prior years.

International Biscuits Company

Yıldız Holding A.Ş. acquired United Biscuit Group as of 3 November 2014. Goodwill accounted at Yıldız Holding’s financial statement related with IBC acquisition is accounted to these financial statement by restating prior years.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

14. INTANGIBLE ASSETS

Movements of intangible assets between 1 January 2020 - 31 March 2020 are as follows:

Cost	1 January 2020	Addition	Currency Translation Differences	31 March 2020
Rights (*)	299.979	1.249	25.055	326.283
Other intangible assets	5.988	491	321	6.800
	305.967	1.740	25.376	333.083

Accumulated Amortization	1 January 2020	Charge for the Period	Currency Translation Differences	31 March 2020
Rights	(11.130)	(160)	(904)	(12.194)
Other intangible assets	(2.649)	(400)	(45)	(3.094)
	(13.779)	(560)	(949)	(15.288)
Net Book Value	292.188			317.795

Movements of intangible assets between 1 January 2019 - 31 March 2019 are as follows:

Cost	1 January 2019	Addition	Currency Translation Differences	31 March 2019
Rights (*)	263.730	1.432	19.739	284.901
Other intangible assets	3.251	51	-	3.302
	266.981	1.483	19.739	288.203

Accumulated Amortization	1 January 2019	Charge for the Period	Currency Translation Differences	31 March 2019
Rights	(6.382)	(1.158)	(395)	(7.935)
Other intangible assets	(2.841)	(79)	-	(2.920)
	(9.223)	(1.237)	(395)	(10.855)
Net Book Value	257.758			277.348

(*) As of 31 March 2020 Rights contain reacquired rights related with Saudi distribution agreements of Groups products in Saudi Arabia amounting to TL 259.259 thousand (31 March 2019: TL 223.943 thousand), the remaining amount of TL 48.347 thousand (31 March 2019: TL 44.012 thousand) contains the rights of Rana brand. Reacquired rights are not subject to depreciation and has indefinite useful life. Impairment test is applied every year of when there is any indicator that impairment may occur.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

14. INTANGIBLE ASSETS (Continued)

The intangible assets are amortized on a straight-line basis over their estimated useful lives.

	Useful Life
Rights	2 years - Indefinite life
Other intangible assets	2 - 12 years
Brand	Indefinite life

15. OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

Guarantees Given

(Balances denominated in foreign currencies have been presented in their original currency)

	31 March 2020			31 December 2019		
	TL	USD	EURO	TL	USD	EURO
A) CPM's given in the name of own legal personality (*)	201.266	25.862	-	201.279	26.273	-
B) CPM's given on behalf of the fully consolidated companies	-	-	87.922	-	-	87.922
C) CPM's given on behalf of third parties for ordinary course of business (**)	-	-	97.270	-	-	97.270
D) Total amount of other CPM's given						
i.Total amount of CPM's given on behalf of the majority shareholder (**)	-	-	-	-	-	-
ii.Total amount of CPM's given on behalf of the group companies which are not in scope of B and C	-	-	-	-	-	-
iii.Total amount of CPM's given on behalf of third parties which are not in scope of C	-	-	-	-	-	-
Total	201.266	25.862	185.192	201.279	26.273	185.192

(*) Non-cash risk amounting to TL 54,9 million and USD 6,3 million.

(**) Includes the warranty given for the group's raw material supplier in relation to the raw material purchases to be made on behalf of the group.

(***) The ratio of other collaterals, pledges and mortgages given by the group to the group's parent company's equity is zero as of 31 March 2020 (31 December 2019: zero).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

15. OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Continued)

Guarantees Given (Continued)

The Company's ultimate parent company Yıldız Holding A.Ş. and some Yıldız Holding Group entities including Ülker Bisküvi's subsidiaries entered into syndicated loan agreement with some of the "creditors" of Yıldız Holding A.Ş. and Yıldız Holding Group entities.

The bank loans of Ülker Bisküvi's subsidiaries which are totally TL 511,1 million and TL 72,4 million contingencies as of 8 June 2018, were increased to the level of Yıldız Holding A.Ş. through syndication. The company's total debt has not increased as a result of the syndicated loan. Related Ülker Bisküvi's subsidiaries became guarantors of Yıldız Holding A.Ş. as of the date of using the loan limited to the current total bank loan risk exposure.

16. REVENUE AND COST OF SALES

a) Revenue

The detail of operating income is as follows:

	1 January - 31 March 2020	1 January - 31 March 2019
Domestic sales(*)	2.699.695	2.173.522
Export sales	397.441	380.331
Sales returns and discounts (-)	(721.010)	(611.493)
Sales Income (net)	2.376.126	1.942.360
Cost of goods sold	(1.635.529)	(1.365.060)
Cost of trade goods sold	(24.316)	(39.128)
Cost of sales	(1.659.845)	(1.404.188)
Gross Profit	716.281	538.172

(*) Denotes domestic sales in Turkey and in countries where abroad subsidiaries are located.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

17. EXPENSES BY NATURE

The detail of operating expenses is as follow:

	1 January - 31 March 2020	1 January - 31 March 2019
General Administrative Expenses		
Personnel expenses	(27.931)	(20.302)
Operating expenses	(22.796)	(6.891)
Consultancy expenses	(6.188)	(2.802)
Depreciation and amortization expenses	(1.398)	(2.624)
Other	(5.503)	(5.994)
	(63.816)	(38.613)
Marketing Expenses		
Marketing operating expenses	(219.741)	(164.182)
Personnel expenses	(34.433)	(32.076)
Rent expenses	(4.664)	(1.310)
Depreciation and amortization expenses	(980)	(777)
Other	(15.812)	(8.459)
	(275.631)	(206.804)
Research Expenses		
Personnel expenses	(3.558)	(2.254)
Materials used	(224)	(301)
Depreciation and amortization expenses	(91)	(107)
Other	(1.809)	(1.174)
	(5.682)	(3.836)

18. INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES

a) The detail of investment income is as follows:

	1 January - 31 March 2020	1 January - 31 March 2019
Foreign exchange gains	689.621	331.079
Interest income	31.291	52.757
Rent income	3.009	2.404
Income on sales of tangible assets	1.317	318
Fair value increase of financial investments	-	166.764
	725.238	553.322

b) The detail of investment expenses is as follows:

	1 January - 31 March 2020	1 January - 31 March 2019
Fair value decrease of financial investments	(568.686)	-
Foreign exchange losses	(103.565)	(23.782)
Loss on sales of tangible assets	(77)	(1.273)
	(672.328)	(25.055)

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

19. FINANCIAL INCOME

	1 January - 31 March 2020	1 January - 31 March 2019
Foreign exchange gain	7.105	1.435
Other	592	570
	7.697	2.005

20. FINANCIAL EXPENSES

	1 January - 31 March 2020	1 January - 31 March 2019
Foreign exchange losses from financing	(428.257)	(221.768)
Interest expenses	(93.500)	(84.113)
Other	(6.636)	(16.499)
	(528.393)	(322.380)

21. TAX ASSET AND LIABILITIES

The Group accounts deferred tax assets and liabilities for temporary timing differences rooted from differences between legal financial statements and financial statements prepared in accordance with TFRS. The differences in question are caused generally by the fact that some profit and loss accounts come up in different periods in legal financial statements and financial statements prepared in accordance with TFRS. These differences are specified below.

Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, deferred tax positions of the firms with deferred tax assets is netted against those with deferred tax liabilities and reflected on a separate-entity basis.

The Law was published in the Official Gazette on 5 December 2017. Accordingly, the corporate income tax rate for all companies will be increased from 20% to 22% for the years 2018, 2019 and 2020. Therefore, deferred tax assets and liabilities shall be measured in accordance with materiality at the tax rate of 22% that are expected to apply to these periods when the assets is realised or the liability is settled, based on the Law that have been enacted. For the periods 2021 and after, the reversals of temporary differences will be measured by 20%. At the same time, the exemption to be applied over the capital gains from the sales of the real estate taxpayers held for at least two years was reduced from 75% to 50% with the regulation published in the Official Gazette dated 5 December 2017.

The rate applied in the calculation of deferred tax assets and liabilities for entities in Turkey is 22% (2019: 22%, 2020: 22%), for entities in Saudi Arabia and Kazakhstan is 20% (2018: 20%), for entities in Egypt 22,5% (2018: 22,5%), and for entity in Kyrgyzstan 10% (2019: 10%), for entity in the United Arab Emirates is zero (2019: Zero).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

21. TAX ASSET AND LIABILITIES (Continued)

Deferred tax bases:

	31 March 2020	31 December 2019	31 March 2020	31 December 2019
Indexation and useful life differences				
of tangible and intangible assets	-	-	1.122.913	1.114.931
Investment properties valuation differences	-	-	17.174	17.174
Marketable securities valuation differences	-	-	89.868	89.868
Derivative instruments	-	-	438.068	358.919
Profit margin elimination on inventories	(13.448)	(12.891)	-	-
Allowance of employee				
termination benefits	(132.899)	(122.368)	-	-
Provision of doubtful receivables	(11.756)	(11.987)	-	-
Previous year losses	(512.850)	(75.059)	-	-
Provision for lawsuits	(6.447)	(6.615)	-	-
Impairment on inventories	(14.570)	(14.986)	-	-
Provision for unused vacation	(18.954)	(16.148)	-	-
Other	(68.715)	(19.390)	4.070	18.088
	(779.639)	(279.444)	1.672.093	1.598.980
	31 March 2020	31 December 2019	31 March 2020	31 December 2019
Indexation and useful life differences				
of tangible and intangible assets	-	-	153.287	151.686
Investment properties valuation differences	-	-	1.717	1.717
Marketable securities valuation differences	-	-	4.493	4.493
Derivative instruments	-	-	96.375	78.962
Profit elimination on inventories	(2.958)	(2.836)	-	-
Allowance of employee termination				
benefits	(26.580)	(24.474)	-	-
Provision of doubtful receivables	(2.586)	(2.637)	-	-
Previous year losses	(111.432)	(15.012)	-	-
Provision for lawsuits	(1.418)	(1.455)	-	-
Impairment on inventories	(3.205)	(3.297)	-	-
Investment incentive	(18.599)	(21.115)	-	-
Provision for unused vacation	(4.170)	(3.553)	-	-
Other	(15.051)	(4.263)	895	3.979
	(185.999)	(78.642)	256.767	240.837

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

21. TAX ASSET AND LIABILITIES (Continued)

Movement of Deferred Tax Liabilities:

	1 January- 31 March 2020	1 January- 31 March 2019
Opening balance	162.195	198.003
Taxes netted from funds recognised under equity	(188)	2.914
Currency translation differences	2.535	1.197
Deferred tax income	(93.774)	(3.942)
	70.768	198.172

As of 31 March 2020, the Group calculated deferred tax assets of TL 512.850 thousand for deductible financial losses in the consolidated financial statements for the current year (31 December 2019: TL 75.059 thousand). The maturities of these losses are as follows:

	31 March 2020	31 December 2019
2025	512.850	75.059
Total	512.850	75.059

Corporate tax

The Company and its Turkish subsidiaries are subject to Turkish corporate taxes. Provision is made in the accompanying financial statements for the estimated charge based on the Group's results for the period.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

The tax rate in 31 March 2020 is 22% (2019: 22%).

In Turkey, advance tax returns are filed on a quarterly basis. The advance corporate income tax rate is 22% in 2020 (2019: 22%).

Losses are allowed to be carried five years maximum to be deducted from the taxable profit of the following years. However, losses occurred cannot be deducted from the profit occurred in the prior years retroactively.

In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1st-25th of April following the close of the accounting year to which they relate. The companies with special accounting periods, file their tax returns between 1st-25th of fourth month after fiscal year end. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

In Turkey, the tax legislation does not permit to file a consolidated tax return. Therefore, provision for taxes, as reflected in the consolidated financial statements, has been calculated on a separate-entity basis.

The corporate tax in Egypt where Hi-Food for Advanced Food Industries and Ülker for Trading and Marketing, a subsidiary of the Group is 22,5% (2019: 22,5%). The corporate tax rate in Saudi Arabia where Food Manufacturers' Company and International Biscuits Company, subsidiaries of the Group is 20% (2019: 20%).

The corporate tax in Kazakhstan where Hamle Company Ltd LLP, a subsidiary of the Group is 20% (2019: 20%).

The corporate tax in Kyrgyzstan where Ülker Star LLC, a subsidiary of the Group is 10% (2019: 10%).

In UAE where Amir Global Trading FZE, a subsidiary of the Group is exempt from corporate tax earnings (2019: exempt).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

21. TAX ASSET AND LIABILITIES (Continued)

Income withholding tax

In addition to corporate taxes, companies should also calculate income withholding taxes and funds surcharge on any dividends distributed, except for companies receiving dividends who are Turkish residents and Turkish branches of foreign companies. Income withholding tax applied in between 24 April 2003 – 22 July 2006 is 10% and commencing from 22 July 2006, this rate has been changed to 15% upon the Council of Ministers' Resolution No: 2006/10731. Undistributed dividends incorporated in share capital are not subject to income withholding tax.

Provision for taxation as of 31 March 2020 and 31 December 2019 is as follows:

	31 March 2020	31 December 2019
Total corporate tax provision	(67.338)	(232.123)
Prepaid taxes and funds	(34.911)	163.156
Taxation in the balance sheet	(102.249)	(68.967)
	1 January - 31 March 2020	1 January - 31 March 2019
Current period corporate tax expense	67.338	108.769
Deferred tax income	(93.774)	(3.942)
Tax expense in the income statement	(26.436)	104.827

22. EARNINGS PER SHARE

A summary of the Group's weighted average number of shares outstanding as of 31 March 2020 and 2019 and computation of earnings per share set out here as follows:

	1 January - 31 March 2020	1 January - 31 March 2019
Weighted average number of common stock outstanding	34.200.000	34.200.000
Net profit	(98.292)	365.476
Basic Earnings per Share	(0,29)	1,07

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES

The detail of receivables from related parties is as follows:

	31 March 2020	31 December 2019
Trade receivables	2.390.615	2.106.741
Non-trade receivables	115.696	115.619
	2.506.311	2.222.360

The detail of trade and non-trade receivables is as follows:

	31 March 2020		31 December 2019	
	Trade	Non-Trade	Trade	Non-Trade
<i>Other Companies Controlled by the Principle Shareholder</i>				
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	990.589	-	901.132	-
Pasifik Tük. Ürün. Satış ve Ticaret A.Ş.	686.923	-	585.481	-
İstanbul Gıda Dış Ticaret A.Ş.	384.594	-	335.393	-
Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş.	183.238	-	159.344	-
G2M Eksper Satış ve Dağıtım Hizmetleri A.Ş.	87.484	-	70.794	-
United Biscuits (UK) Ltd.	2.953	-	2.788	-
Other (*)	54.834	115.696	51.809	115.619
	2.390.615	115.696	2.106.741	115.619

(*) 114.855 thousand of TL portion of other receivables is the amount of receivables arised from the sales of Istanbul Gıda Dış Ticaret A.Ş.

The Group's trade receivables from related parties mainly arise from sales to Horizon Hızlı Tüketim Ürünleri Pazarlama Satış ve Tic. A.Ş. and Pasifik Tük. Ürün. Satış ve Ticaret A.Ş. those make the sale and distribution of products throughout Turkey.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)

The detail of advances given to related parties is as follow:

	31 March 2020	31 December 2019
Önem Gıda San. ve Tic. A.Ş.	37.856	41.545
	37.856	41.545

The detail of payables to related parties is as follows:

	31 March 2020	31 December 2019
Trade payables	534.128	607.365
Non-trade payables	3.100	113
	537.228	607.478

The detail of trade and non-trade payables to related parties is as follows:

	31 March 2020		31 December 2019	
	Trade	Non-Trade	Trade	Non-Trade
Principle Shareholder				
Yıldız Holding A.Ş.	79.879	-	96.125	-
Other Companies Controlled by the Principle Shareholder				
Önem Gıda San. ve Tic. A.Ş.	291.249	30	385.307	-
İstanbul Gıda Dış Ticaret A.Ş.	78.998	92	73.058	104
United Biscuits (UK) Ltd.	24.406	2.123	7.925	-
Besler Gıda ve Kimya San. ve Tic. A.Ş.	15.645	-	8.466	-
Adapazarı Şeker Fabrikası A.Ş.	11.576	-	8.268	-
pladis Foods Limited	14.596	855	4.491	-
Marsa Yağ San. ve Tic. A.Ş.	3.441	-	2.409	-
CCC Gıda San. ve Tic. A.Ş.	583	-	564	-
Other	13.755	-	20.752	9
	534.128	3.100	607.365	113

The detail of due to related parties as loan payable is as follows:

	31 March 2020	31 December 2019
Yıldız Holding A.Ş.	127.648	84.327
	127.648	84.327

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
 ORIGINALLY ISSUED IN TURKISH
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
 31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)

The detail of purchases from and sales to related parties is as follows:

	1 January - 31 March 2020		1 January - 31 March 2019	
	Purchases	Sales	Purchases	Sales
<i>Other Companies Controlled by the Principle Shareholder</i>				
Önem Gıda San. ve Tic. A.Ş.	576.470	134	491.783	312
Besler Gıda ve Kimya San. ve Tic. A.Ş.	82.098	33	65.492	-
İstanbul Gıda Dış Tic. A.Ş.	74.106	277.948	-	-
United Biscuits (UK) Ltd.	24.302	913	27.292	31.080
Marsa Yağ San. ve Tic. A.Ş.	20.431	-	17.966	-
Pendik Nişasta San. A.Ş.	14.546	-	13.396	-
CCC Gıda San. ve Tic. A.Ş.	14	9	11.836	30
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	4	819.339	91	737.485
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	-	509.998	-	349.363
Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş.	-	78.903	-	73.652
Other	6.233	59.310	5.111	82.784
	798.204	1.746.587	632.967	1.274.706

The Group mainly acquires raw materials from Besler Gıda ve Kimya Sanayi ve Ticaret A.Ş., which produces vegetable oil and margarine, Önem Gıda San. ve Tic. A.Ş and Pendik Nişasta San. A.Ş.. The major part of selling and distribution operations of the Group all Turkey are operated by Horizon Hızlı Tüketim Ürünleri Pazarlama Satış ve Tic. A.Ş. and Pasifik Tük. Ürün. Satış ve Ticaret.

The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows;

For the three months period ended 31 March 2020:

	Rent Income/(Expense) Net	Service Income/(Expense) Net	Interest and Foreign Exchange Income/(Expense) Net
<i>Principle Shareholder</i>			
Yıldız Holding A.Ş.	6	(57.368)	10.430
<i>Other Companies Controlled by the Principle Shareholder</i>			
pladis Foods Limited	-	(14.596)	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	-	(3.775)	12.157
United Biscuits (UK) Ltd.	-	(3.427)	129
Önem Gıda San. ve Tic. A.Ş.	779	(2.737)	2.462
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	18	(1.892)	5.094
İzsal Gayrimenkul Geliştirme A.Ş.	(395)	(739)	-
CCC Gıda San. ve Tic. A.Ş.	(214)	(116)	-
Besler Gıda ve Kimya San. Ve Tic. A.Ş.	-	-	(49)
İstanbul Gıda Dış Tic. A.Ş.	-	287	50.755
Other	391	(1.403)	(3.093)
	585	(85.766)	77.885

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)

For the three months period ended 31 March 2019:

	Rent Income/(Expense) Net	Service Income/(Expense) Net	Interest and Foreign Exchange Income/(Expense) Net
Principle Shareholder			
Yıldız Holding A.Ş.	(91)	(49.793)	5.146
Other Companies Controlled by the Principle Shareholder			
Önem Gıda San. ve Tic. A.Ş.	640	(4.757)	854
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	36	(3.997)	11.055
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	8	(3.396)	19.751
United Biscuits (UK) Ltd.	9	(58)	2.003
İzsal Gayrimenkul Geliştirme A.Ş.	(492)	(461)	-
CCC Gıda San. ve Tic. A.Ş.	(187)	413	(648)
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	16	(1.018)
Other	411	(259)	5.371
	334	(62.292)	42.514

Benefits provided to members of BOD and key management personnel:

	31 March 2020	31 December 2019
Fees and other short term benefits	7.979	7.552
	7.979	7.552

24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT

Foreign currency risk management

Transactions in foreign currencies expose the Group to foreign currency risk.

This risk mainly arises from fluctuation of foreign currency used in conversion of foreign assets and liabilities into Turkish Lira. Foreign currency risk arises as a result of trading transactions in the future and the difference between the assets and liabilities recognized. In this regard, the Group manages this risk with a method of netting foreign currency denominated assets and liabilities. The management reviews the foreign currency open position and provides measures when needed.

The group mainly faces USD, EUR, GBP, CHF and DKK currency risks.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

Foreign Currency Risk Management (continued)

The foreign currency denominated assets and liabilities of monetary and non-monetary items are as follows:

	31 March 2020				
	TL	USD	EUR	GBP	CHF
1. Trade Receivables	377.968	45.684	8.496	2.357	-
2a. Monetary Financial Assets	5.235.878	799.591	1.886	1.479	32
2b. Non-Monetary Financial Assets	-	-	-	-	-
3. Other	11.135	600	968	30	-
4. CURRENT ASSETS	5.624.981	845.875	11.350	3.866	32
5. Trade Receivables	-	-	-	-	-
6a. Monetary Financial Assets	-	-	-	-	-
6b. Non-Monetary Financial Assets	-	-	-	-	-
7. Other	-	-	-	-	-
8. NON-CURRENT ASSETS	-	-	-	-	-
9. TOTAL ASSETS	5.624.981	845.875	11.350	3.866	32
10. Trade Payables	155.390	13.724	5.789	2.775	270
11. Financial Liabilities	5.560.635	252.713	542.475	-	-
12a. Other Monetary Financial Liabilities	5.703	739	123	-	-
12b. Other Non-monetary Financial Liabilities	1.943	183	104	-	-
13. CURRENT LIABILITIES	5.723.671	267.359	548.491	2.775	270
14. Trade Payables	-	-	-	-	-
15. Financial Liabilities	413.352	-	57.291	-	-
16a. Other Monetary Financial Liabilities	-	-	-	-	-
16b. Other Non-monetary Financial Liabilities	-	-	-	-	-
17. NON-CURRENT LIABILITIES	413.352	-	57.291	-	-
18. TOTAL LIABILITIES	6.137.023	267.359	605.782	2.775	270
19. Net Assets of Off Statement of Financial Position (19a-19b)	972.306	116.000	30.000	-	-
19a. Net Assets of Off Statement of Financial Position	-	-	-	-	-
19b. Net Liabilities of Off Statement of Financial Position	(972.306)	(116.000)	(30.000)	-	-
20. Net Foreign Currency Asset / (Liability) Position (9-18+19)	460.264	694.516	(564.432)	1.091	(238)
21. Monetary Items Net Foreign Currency Asset / (Liability) Position (1+2a+5+6a-10-11-12a-14-15-16a)	(521.234)	578.099	(595.296)	1.061	(238)
22. Total Fair Value of Financial Instruments Used to Hedge the Foreign Currency Position	438.068	52.082	13.680	-	-
23. Total value of Hedged Foreign Currency Assets	-	-	-	-	-
24. Total value of Hedged Foreign Currency Liabilities	-	-	-	-	-

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

Foreign Currency Risk Management (continued)

	31 December 2019				
	TL	USD	EUR	GBP	CHF
1. Trade Receivables	383.292	51.020	8.896	2.708	-
2a. Monetary Financial Assets	5.388.027	901.935	3.636	785	11
2b. Non-Monetary Financial Assets	-	-	-	-	-
3. Other	5.167	268	522	14	1
4. CURRENT ASSETS	5.776.498	953.223	13.054	3.507	12
5. Trade Receivables	-	-	-	-	-
6a. Monetary Financial Assets	-	-	-	-	-
6b. Non-Monetary Financial Assets	-	-	-	-	-
7. Other	-	-	-	-	-
8. NON-CURRENT ASSETS	-	-	-	-	-
9. TOTAL ASSETS	5.776.498	953.223	13.054	3.507	12
10. Trade Payables	100.636	10.497	4.454	917	251
11. Financial Liabilities	5.124.763	259.148	539.105	-	-
12a. Other Monetary Financial Liabilities	7.751	1.166	124	-	-
12b. Other Non-monetary Financial Liabilities	2.867	393	80	-	-
13. CURRENT LIABILITIES	5.236.017	271.204	543.763	917	251
14. Trade Payables	-	-	-	-	-
15. Financial Liabilities	379.476	-	57.058	-	-
16a. Other Monetary Financial Liabilities	-	-	-	-	-
16b. Other Non-monetary Financial Liabilities	-	-	-	-	-
17. NON-CURRENT LIABILITIES	379.467	-	57.058	-	-
18. TOTAL LIABILITIES	5.615.484	271.204	600.821	917	251
19. Net Assets of Off Statement of Financial Position (19a-19b)	888.581	116.000	30.000	-	-
19a. Net Assets of Off Statement of Financial Position	-	-	-	-	-
19b. Net Liabilities of Off Statement of Financial Position	(888.581)	(116.000)	(30.000)	-	-
20. Net Foreign Currency Asset / (Liability) Position (9-18+19)	1.049.595	798.019	(557.767)	2.590	(239)
21. Monetary Items Net Foreign Currency Asset / (Liability) Position (1+2a+5+6a-10-11-12a-14-15-16a)	158.702	682.144	(588.209)	2.576	(240)
22. Total Fair Value of Financial Instruments Used to Hedge the Foreign Currency Position	358.919	46.403	12.522	-	-
23. Total value of Hedged Foreign Currency Assets	-	-	-	-	-
24. Total value of Hedged Foreign Currency Liabilities	-	-	-	-	-

The Group's export and import balances for the three month period presented below:

	1 January - 31 March 2020	1 January - 31 March 2019
Total exports	397.441	380.331
Total imports	132.5079	97.447

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

Foreign currency risk sensitivity

The Group is exposed to foreign exchange risk arising primarily from USD and EUR. The table below shows, the foreign currency sensitivity of the Company arising from 10% change in US dollar and EUR rates. The rate used as 10% is a fair benchmark for the Company as it is limited to capital commitment threshold. This rate is the anticipated rate change of the Company's senior management. Sensitivity analysis includes only the monetary items in foreign currency at year end and shows the effect of 10% increase in USD and in EUR foreign currency rates. Negative value implies the effect of 10% increase in USD and in EUR foreign currency rates against TL on the decrease in the net profit.

	1 January - 31 March 2020		1 January - 31 March 2019	
	Income / Expense		Income / Expense	
	Appreciation of foreign currency	Depreciation of foreign currency	Appreciation of foreign currency	Depreciation of foreign currency
In case of %10 appreciation of USD against TL				
1 - US Dollar net asset / liability	452.275	(452.275)	362.249	(362.249)
2- Part of hedged from US Dollar risk (-)				
3- US Dollar net effect (1 +2)	452.275	(452.275)	362.249	(362.249)
In case of %10 appreciation of EUR against TL				
4 -Euro net asset / liability	(407.861)	407.861	(349.931)	349.931
5 - Part of hedged from Euro risk (-)				
6- Euro net effect (4+5)	(407.861)	407.861	(349.931)	349.931
Total (3 + 6)	44.414	(44.414)	12.318	(12.318)

25. FINANCIAL INSTRUMENTS

Fair Value of Financial Assets

Fair value measurements by level of the following fair value measurement hierarchy is as follows:

- Level 1: Quoted prices in active markets for identical assets or liabilities
- Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).
- Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs)

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

25. FINANCIAL INSTRUMENTS (Continued)

Fair Value of Financial Assets (continued)

The classification of the Company's financial assets and liabilities at fair value is as follows:

	31 March 2020	Fair value hierarchy as of reporting date		
		Level 1 TL	Level 2 TL	Level 3 TL
Financial assets				
Financial assets at fair value through profit and loss				
- Shares	3.820.230	776	3.815.172	4.282
Financial assets at fair value through comprehensive income statement				
- Shares	945.829	-	-	945.829
- Derivative instruments	438.068	-	438.068	-
Total	5.204.127	776	4.253.240	950.111

	31 December 2019	Fair value hierarchy as of reporting date		
		Level 1 TL	Level 2 TL	Level 3 TL
Financial assets				
Financial assets at fair value through comprehensive income statement				
- Shares	4.080	806	-	3.274
Financial assets at fair value through comprehensive income statement				
- Shares	945.829	-	-	945.829
- Derivative instruments	358.919	-	358.919	-
Total	1.308.828	806	358.919	949.103

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS
ORIGINALLY ISSUED IN TURKISH
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
31 MARCH 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

26. EVENTS AFTER THE BALANCE SHEET DATE

The Group has used a total of 455 million US Dollars with a maturity of 3 years, 6-month interest payments, with the participation of 7 international banks which are led by Bank of America (Global Coordinator and Accredited Lead Co-Organizer), Coöperatieve Rabobank U.A (Authorized Leading Co-Organizer)) and Emirates NBD Bank Capital Limited, and as well as European Bank For Reconstruction and Development (EBRD). The loan used consists of syndication slices of \$ 110 million and € 244 million, as well as a loan agreement of € 75 million signed with the EBRD. The related financing is planned to be used in closing the syndication loan of USD 375 million, which expired in April 2020, and in the strategic investment projects of the Group.